Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
EB06
product2 mentionslast seen Nov 9, 2026
A fully human monoclonal antibody targeting CXCL10 for the treatment of vitiligo.
Relationships 5
Relationship
Edesa Biotech, Inc.developsEB06
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 9, 2026Edesa Biotech, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 1.02: Termination of a Material Definitive Agreement; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate
- filingSEC EDGAROct 15, 2026Edesa Biotech, Inc. 8-K: Item 8.01: Other Events
Edesa Biotech, Inc. (the "Company") reported that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigational New Drug ("IND") application for its Phase 2 clinical study of EB06